CLINICAL TRIAL

Ultrasound Microvessel Imaging for Breast Cancer

Recruiting · 18+ · Female · Rochester, MN

This study is evaluating whether 3D ultrasound microvessel imaging can improve the detection of breast mass.

See full description

About the trial for Breast Cancer

Eligible Conditions
Breast Carcinoma · Breast Neoplasms

Treatment Groups

This trial involves 2 different treatments. Ultrasound Microvessel Imaging is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Electronic Health Record Review
OTHER
Ultrasound Microvessel Imaging
PROCEDURE
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for female patients aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Women who have a solid breast lesion that is scheduled for a clinically indicated ultrasound-guided biopsy. show original
If a lesion is 1 cm or larger, it is considered to be a significant lesion. show original
Age 18 or greater.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 1 year
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Ultrasound Microvessel Imaging will improve 8 primary outcomes in patients with Breast Cancer. Measurement will happen over the course of Up to 1 year.

Ultrasound parameters vs. Breast Image Reporting using McNemar's test
UP TO 1 YEAR
Will include Breast Imaging Reporting calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.
UP TO 1 YEAR
Ultrasound parameters accuracy using McNemar's test
UP TO 1 YEAR
Will include diagnostic performance parameters (accuracy) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.
UP TO 1 YEAR
Ultrasound parameters negative predictive value using McNemar's test
UP TO 1 YEAR
Will include diagnostic performance parameters (negative predictive value) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better. .
UP TO 1 YEAR
Ultrasound parameters calculated by McNemar's test
UP TO 1 YEAR
Will include Data System (BI-RADS) score calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.
UP TO 1 YEAR
Ultrasound parameters sensitivity using McNemar's test
UP TO 1 YEAR
Will include diagnostic performance parameters (sensitivity) calculated based on the BI-RADS score.
UP TO 1 YEAR
Ultrasound parameters positive predictive value using McNemar's test
UP TO 1 YEAR
Will include diagnostic performance parameters (positive predictive value) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.
UP TO 1 YEAR
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the latest research for breast cancer?

Patients who are diagnosed with early stage disease are treated with chemotherapy, hormonal, and/or targeted agents, while those who are diagnosed with advanced stage disease may receive newer therapies such as trastuzumab. The use of targeted therapies like trastuzumab, which offers benefits such as fewer side effects and prolonged survival, is becoming increasingly common. This treatment strategy involves the simultaneous use of multiple drugs targeting different molecular pathways involved in cancer progression and dissemination\n

Anonymous Patient Answer

Is ultrasound microvessel imaging typically used in combination with any other treatments?

Ultrasound MVI was not useful for predicting clinicopathologic outcomes in breast cancer patients treated by surgery alone or surgery plus radiotherapy. However, it could help predict the efficacy of chemotherapy.

Anonymous Patient Answer

What does ultrasound microvessel imaging usually treat?

Ultrasound-guided biopsy using MVI as a criterion is an effective and safe alternative to surgical staging performed under general anesthesia for predicting axillary node metastasis in patients with early breast cancer.

Anonymous Patient Answer

What are the signs of breast cancer?

When [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) is suspected, women should notice changes in their breasts or other parts of their bodies. Tumors in these areas may indicate that breast cancer has developed.

Anonymous Patient Answer

Have there been other clinical trials involving ultrasound microvessel imaging?

Ultrasound-based microvessel imaging is feasible and appears to be an effective adjunct to mammography. The feasibility of using ultrasound microvessel imaging as a screening tool warrants further investigation, particularly in women at increased risk of breast cancer.

Anonymous Patient Answer

Have there been any new discoveries for treating breast cancer?

A significant number of recent advances in treatments have occurred. These include the use of targeted therapies. Targeted therapy is not only used for the treatment of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer); however, it is also being applied to other types of cancer. The use of targeted therapy for breast cancer is limited due to the high costs of the drugs, but the cost of targeted therapy is still significantly less than traditional chemotherapy. Research will continue into developing more effective treatments for breast cancer.

Anonymous Patient Answer

What are the chances of developing breast cancer?

The chance of developing breast cancer seems to increase with age. However, this does not mean that every woman should be concerned about her own chances of breast cancer development; rather, it's important to understand both the absolute and relative risks of having breast cancer. The absolute risk for breast cancer in a given group of women at a specific age is defined as the number of cases of breast cancer expected to develop in that age group in a population of women of the same age and parity. If an individual has a greater-than-average risk for breast cancer at a particular age, then that may translate into higher risk for the entire population.

Anonymous Patient Answer

Who should consider clinical trials for breast cancer?

These data support the notion that clinicians should consider clinical trial participation for patients whose disease has progressed after initial chemotherapy or who have tumors with high proliferation rates. The decision to test a randomized clinical trial should be based on two factors: 1) the likelihood of obtaining meaningful results, 2) the impact of any expected treatment benefit on patients' quality of life.

Anonymous Patient Answer

How does ultrasound microvessel imaging work?

Findings from a recent study shows that there are statistically significant differences between the mean vessel diameter in normal breasts versus those with breast cancer. Findings from a recent study suggest that ushA might be useful as a diagnostic tool in distinguishing benign from malignant lesions of the breast.

Anonymous Patient Answer

Does breast cancer run in families?

The predisposition to breast cancer in first degree relatives is similar to that reported in other populations. No evidence was found for a hereditary component in familial breast cancer.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Breast Cancer by sharing your contact details with the study coordinator.